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Highlights 
 
 We perform a meta-analysis of diabetes treatment effects on depression 
 We also test for correlates of response: glycaemia, insulin resistance & inflammation 
 Pioglitazone consistently improves depressive symptoms, most strongly in women 
 Metformin has no overall benefit on depressive symptoms compared to controls 
 Elevated inflammation is implicated in the anti-depressant effects of pioglitazone 
 
Abstract 
 
Depression is a common comorbidity in diabetes but conventional anti-depressant treatments 
do not consistently improve outcomes. We tested whether established diabetes treatments can 
also improve depressive symptoms and additionally examined biological correlates of 
response. We performed a multi-database systematic search of all clinical trials, which 
measured the effect of licensed diabetes treatments on depressive symptoms using a validated 
questionnaire. Results of randomised controlled trials (RCT’s) were pooled for meta-analysis. 
Data were also collected on insulin resistance (HOMA-IR), C-reactive protein (CRP) and 
fasting blood glucose (FBG) as correlates of response. Nineteen studies (n=3369 patients) 
were included in the qualitative synthesis, 9 testing thiazolidenediones, 5 metformin, 2 
thiazolidenediones against metformin, 2 incretin-based therapies and 1 insulin. Most studies 
were of good quality. In random-effects meta-analysis of RCT’s, pioglitazone improved 
depressive symptoms compared to controls (pooled effect size = -0.68 (95% C.I. -1.12 to -
0.24), p=0.003, Nstudies=8, I
2 =83.2%). Conversely, metformin was comparable to controls 
overall (pooled effect size = +0.32 (95% C.I. -0.23 to 0.88), p=0.25, Nstudies=6, I
2=94.2%), 
although inferior to active controls (pooled effect size = +1.32 (95% C.I. 0.31 to 2.34), 
p<0.001, Nstudies=3, I
2=90.1%). In random-effects meta-regression, female sex (β=-0.023, 
(95% C.I.-0.041 to -0.0041), p=0.016, Nstudies=8) predicted reduction in depressive symptoms 
with pioglitazone, but baseline HOMA-IR,FBG and severity of depressive symptoms did not. 
In conclusion, pioglitazone was associated with improvement in depressive symptoms, an 
effect more marked in women and poorly explained by effects on glycaemia and insulin 
resistance. Metformin had no consistent benefit on depressive symptoms. Larger trials are 
needed, stratified by sex and including serial measures of innate inflammation. 
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1. Introduction 
 
Depressive symptoms are twice as common in people with type 2 diabetes compared to the 
general population and are associated with increased risk of diabetes complications and 
premature mortality (Anderson et al., 2001; Winkley et al., 2012). However, this association 
is inadequately explained by behavioural and psychological factors alone (Moulton et al., 
2015). Conventional treatments for depressive symptoms in type 2 diabetes, such as anti-
depressant medication and psychological therapies, are associated with high rates of 
treatment failure and frequent non-adherence to treatment (Rush et al., 2006; Sawada et al., 
2009). Understanding the biological mechanisms underlying depressive symptoms in type 2 
diabetes could lead to identifying new targets and development of novel treatments.  
 
At least three potential (though not mutually exclusive) biological pathways have been 
implicated in the link between the two conditions. Firstly, increased concentrations of 
circulating inflammatory markers are seen in people with depressive symptoms and type 2 
diabetes compared to people with type 2 diabetes alone (Hayashino et al., 2014; Laake et al., 
2014). Secondly, higher insulin resistance is consistently associated with increased depressive 
symptoms in cross-sectional studies, even after adjustment for confounders (Kan et al., 2013), 
and insulin resistance is likewise associated with elevated inflammation (Donath, 2014). 
Thirdly, hyperglycaemia is associated with increased depressive symptoms in cross-sectional 
studies (Lustman et al., 2000), although the association is weaker when tested prospectively 
(Fisher et al., 2010b). Importantly, conventional antidepressants have inconsistent effects on 
glycaemic control, insulin resistance and inflammation (Katon et al., 2004; Kauffman et al., 
2005), whereas many diabetes treatments have potent effects on these three pathways 
(Makdissi et al., 2012; Reynolds et al., 2007; Yki-Jarvinen, 2004). Meanwhile, many diabetes 
treatments, including metformin, glucagon-like peptide-1 (GLP-1) and thiazolidenediones, 
have been found to cross the blood-brain barrier (Heneka et al., 2005; Kastin et al., 2002; 
Labuzek et al., 2010). As well as reducing polypharmacy, this suggests that established 
diabetes treatments could be repurposed to improve both depressive symptoms and diabetes 
concurrently. In addition to possible central actions, such anti-depressant effects could be 
driven by the modification of biological pathways common to both depressive symptoms and 
diabetes. To date, however, the potential anti-depressant properties of diabetes treatments 
have not been systematically evaluated. 
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We have conducted a systematic review and meta-analysis of diabetes treatments and their 
effects upon depressive symptoms. Our primary aim was to test whether specific 
pharmacological classes of diabetes treatments are associated with improvements in 
depressive symptoms compared to controls. Our secondary aim was to test for potential 
correlates of treatment response, specifically inflammation, insulin resistance and glycaemic 
control. 
 
2. Methods 
 
 
2.1. Design 
This systematic review follows the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines, in which studies that meet review criteria are 
examined and those that were RCTs and with sufficient data pooled for meta-analysis. 
 
2.2. Literature search 
We systematically searched PubMed, EMBASE and Web of Science from 1st January 1900 to 
1st  March 2018. A Boolean search was conducted, cross-referencing licensed 
pharmacological treatments of diabetes with depressive symptoms and related terms, with 
exclusion of non-human studies and limiting to clinical trials only. Notably, we included 
randomised- and non-randomised trials in the qualitative synthesis but only RCT’s in the 
meta-analysis. The search strategy was as follows:  
 
(sglt-2 inhibitor OR dapagliflozin  OR canagliflozin OR empagliflozin OR metformin OR 
incretin OR dpp-iv inhibitor OR dpp-4 inhibitor OR linagliptin OR saxagliptin OR alogliptin 
OR sitagliptin OR nateglinide OR repaglinide OR albiglutide OR glp-1 OR dulaglutide OR 
exenatide OR liraglutide OR meglitinide OR pioglitazone OR rosiglitazone OR glipizide OR 
glyburide OR repaglinide OR acarbose OR insulin OR glimepiride OR gliclazide OR 
glipizide OR chlorpropamide OR tolazamide OR tolbutamide OR sulphonylurea) AND 
(mood OR depress* OR dysthym*) NOT (rat* OR mouse OR mice).  
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A parallel search of potentially grey/unpublished literature (OpenGrey, DART-Europe, 
EThOS, clinicaltrials.gov and the WHO International Clinical Trials Registry Platform 
clinical trials databases) was also conducted.   
 
Two authors (C.M. and C.H.) independently performed the literature search and resolved 
differences over inclusion through discussions and consensus. Titles were reviewed and then 
abstracts were reviewed for titles meeting inclusion criteria. From abstracts fulfilling 
inclusion criteria, full-text articles were reviewed and data extraction performed for studies 
still meeting inclusion criteria. The reference lists of included papers were checked for 
additional publications. Both published and unpublished articles were included, and authors 
were contacted where data were missing.  
 
2.3. Study selection 
The search was restricted to clinical trials, including controlled and uncontrolled trials. 
Specific inclusion criteria were: (1) study was a clinical trial testing a licensed diabetes 
treatment at licensed dose and route; (2) depressive symptoms were measured pre- and post-
treatment using a validated depression scale either as primary or secondary outcome; (3) a 
minimum of 5 patients were recruited; and (4) the sample consisted of adults (18 years of age 
or more). Exclusion criteria were (1) study was an observational study; (2) study was a case 
report, case series or review article presenting no original data; (3) study was not published in 
English; (4) the measure of depressive symptoms was a sub-score of a general quality-of-life 
measure; and (5) patients with depression were specifically excluded from the study. Figure 1 
shows the PRISMA flow diagram of the search.  
 
[Figure 1 here] 
 
2.4. Data extraction  
Studies were stratified into those selecting only patients with depression at baseline and those 
which did not specifically select for depression. Studies in which depression was specifically 
excluded were not included in our synthesis. For each study, we extracted the following data: 
study design; baseline depressive symptoms; baseline diabetes status; sample size; sex; 
neuropsychiatric comorbidity of the sample; type, dose, route and duration of intervention 
and control treatment; measure of depressive symptoms; mean (SD) change in depressive 
symptoms for each group; and significant adverse effects. In order to test for potential 
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correlates of change in depressive symptoms, we also extracted data on glycaemic control 
(fasting blood glucose (FBG) and HbA1c), insulin resistance and inflammatory markers, 
including baseline measures and their mean (SD) change following treatment. We also 
searched for duplicate publications for each trial to extract further data. Where raw values of 
insulin resistance were not presented but FBG and fasting insulin were available, the 
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) formula was used to 
derive insulin resistance (Matthews et al., 1985). Where the SD was not presented for change 
in depressive symptoms, FBG, insulin resistance or inflammation, we estimated this by 
assuming that the true SDs at baseline and follow-up were constant and the correlation 
between patient’s baseline and follow-up values was moderately positive (r=0.5). If a study 
reported several follow-up time points, the longest follow-up interval was used. For studies 
with multiple arms, data were extracted only for pharmacological treatments or placebo. For 
studies testing a treatment at different doses, the mean score and SD was calculated, weighted 
according to numbers in each group. 
 
2.5. Quality assessment 
We assessed quality using the Cochrane Common Mental Disorders Depression Anxiety & 
Neurosis Group (CCDAN) instrument (19). This was chosen because it was specifically 
developed for trials of treatments for depression and can be used for both randomised- and 
non-randomised trials (Cipriani et al., 2007; Moncrieff J, 2001). The scale consists of 23 
items, each scored 0-2 and each contributing equally to a final score between 0-46, higher 
scores indicating higher quality. The CCDAN covers aspects of both internal validity (or 
control of bias) and external validity. A cut-off score of more than 20 has been suggested to 
identify high-quality studies (Cipriani et al., 2007).  
 
2.6. Statistical analysis 
Using the metan command in STATA 11.0, we performed meta-analysis for any drug class 
tested in at least 5 RCTs. For each study, effect-size estimates were calculated using the 
standardized mean difference (SMD) in change in depressive symptoms following treatment. 
This was calculated by dividing the mean difference by the pooled SD of the change scores 
within the group (equivalent to Cohen’s d). SMD is an appropriate measure of effect estimate 
when studies assess the same variable but measure it using different questionnaires (Egger et 
al.). The standard error (SE) of each study’s group sizes was calculated according to a 
formula provided by Cooper and Hedges (Cooper and Hedges, 1994).  
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Next, studies were weighted using an inverse-variance method, such that studies with larger 
precision were given greater weight. Pooled effect estimates were calculated using a random-
effects model, which allows for heterogeneity between studies by permitting the true effects 
estimated by the studies to differ between studies. The combined effect thus represents the 
mean of the population of true effects and is appropriate where effects may vary between 
populations (Borenstein M, 2009). This is expected in this meta-analysis where there is 
variation in dose, treatment duration, severity of depressive symptoms and metabolic status at 
baseline. In addition to presenting an overall effect size, Forest plots were stratified into 
studies using placebo controls and active controls (e.g. other diabetes treatments). 
Heterogeneity between studies was quantified by calculating the I2 statistic, which represents 
the fraction of variation between studies attributable to heterogeneity. Values for I2 range 
between 0% and 100% with values of 25%, 50% and 75% suggesting low, moderate and high 
heterogeneity respectively (Higgins et al., 2003). Using all studies in the meta-analysis, we 
assessed potential publication bias by using the non-parametric Trim and fill test and Egger’s 
test of small study effects (Egger et al., 1997). Because fewer than 10 studies were included 
in the meta-analysis, a Funnel plot was not presented (Sterne et al., 2011). 
 
For any drug class tested in meta-analysis, we performed random-effects meta-regression 
using the following covariates in turn, which were selected a priori: age, sex (percentage 
male), baseline severity of depressive symptoms (% of maximum score on the questionnaire 
used), baseline FBG, baseline HOMA-IR and baseline C-reactive protein (CRP). Data were 
insufficient to test changes over time in FBG, HOMA-IR or CRP as covariates. Because of 
the small number of studies, we firstly used the Monte Carlo permutation test for meta-
regression, which calculates a moment-based estimate of between-study variance and 
provides robust p-values and standard error (SE) associated with each covariate (Harbord 
RM, 2008). To ensure sufficient precision, 10000 permutations were used for each covariate 
(Manly, 2006). This technique reduces the chance of false-positive findings in meta-
regression analyses (Higgins and Thompson, 2004). The effect size of any significant 
covariate was then quantified using the restricted maximum likelihood estimate of between-
study variance, in order to quantify its effect size and effect on overall heterogeneity. 
  
 
3. Results 
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A total of 2490 titles were reviewed, of which 154 abstracts were read and 59 manuscripts 
carried forward for full-text extraction. From these, 19 were included in the qualitative 
synthesis and 12 included in meta-analysis. Of the 19 included studies, 9 tested 
thiazolidenediones, 5 tested metformin, 2 thiazolidenediones versus metformin, 2 incretin-
based therapies and 1 insulin. The total number of patients included was 3369 with mean age 
49.89 years. Fourteen studies were RCTs, 1 was a non-randomised controlled trial and 4 were 
pre-post open label studies.  All RCTs were of good quality, whereas quality of open-label 
non randomised studies was poorer overall (Table 1). The full breakdown in CCDAN scoring 
for each study is included as supplementary material (Supplementary Table 1).  
  
 
3.1. Qualitative synthesis 
3.1.1. Thiazolidenediones 
3.1.1.1. Randomised controlled trials 
Of the 8 RCTs testing pioglitazone, 6 were placebo-controlled (Calabrese, 2017; Lin et al., 
2015; Roohafza et al., 2014; Sepanjnia et al., 2012; Simuni T., 2015; Zeinoddini et al., 2015) 
and two used metformin as a control (Hu et al., 2015; Kashani et al., 2013). Apart from one 
study (Lin et al., 2015), all RCTs selecting depressed patients at baseline reported significant 
reduction in depressive symptoms compared to controls. There was population heterogeneity 
in terms of comorbidity, age and sex (Table 1). Where measured, improvement in depressive 
symptoms was not accompanied by significant change in FBG or insulin resistance. There 
was no correlation between change in insulin resistance and change in depressive symptoms 
where reported (Kashani et al., 2013). In the one RCT in which CRP was reported, positive 
effects on depressive symptoms were paralleled by significant reduction in CRP (Roohafza et 
al., 2014) (Table 2).  
 
3.1.1.2. Non-randomised trials 
Of the three open-label studies, two testing pioglitazone and one rosiglitazone (Kemp et al., 
2012; Kemp et al., 2014; Rasgon et al., 2010), all reported significant reduction in depressive 
symptoms as primary outcome. However, all were small in size (Table 1). The two open-
label trials of pioglitazone reported significant pre-post effects on depressive symptoms, 
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glycaemic control, insulin resistance and inflammation (Kemp et al., 2012; Kemp et al., 
2014). Whereas one of these reported a significant correlation between change in depressive 
symptoms and HOMA-IR (Kemp et al., 2012), the other reported a similar for interleukin-6 
(Kemp et al., 2014) (Table 2).  
 
[Table 1 here] 
 
[Table 2 here] 
 
3.1.2. Metformin 
3.1.2.1. Randomised controlled trials 
Three trials of metformin used placebo controls. In an RCT selecting patients with depression 
at baseline, 24 weeks of metformin treatment in patients with type 2 diabetes led to 
significant reduction in depressive symptoms compared to placebo (Guo et al., 2014), which 
was paralleled by improvement in FBG. However, correlation between FBG change and 
change in depressive symptoms was not reported, nor were data on insulin resistance or 
inflammation. In an unpublished 16-week trial of metformin in overweight people with 
depression all receiving sertraline, metformin performed similarly to placebo, although 
significance values have not been reported (Lustman, 2018).  In the 1-year diabetes 
prevention study of people with impaired glucose tolerance (IGT), metformin significantly 
reduced CRP and fasting glucose, yet was not associated with reduction in the Beck 
Depression Inventory (BDI) score (a secondary outcome) compared to placebo (Ackermann 
et al., 2009). However, the baseline BDI score was very low, limiting scope for potential 
effects (Table 1, Table 2).  
 
Three trials of metformin used active controls. In the two aforementioned RCT’s against 
pioglitazone, metformin was inferior in reducing depressive symptoms in patients with 
depression (Hu et al., 2015; Kashani et al., 2013). In a 12-week trial of women with 
polycystic ovarian syndrome, myo-inositol was marginally superior to metformin in reducing 
depressive symptoms. The population was not selected for depression at baseline and data on 
FBG, insulin resistance or inflammation were not reported (Jamilian et al., 2017). 
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3.1.2.2. Non-randomised trials 
In a non-randomised trial of a sample including people with type 2 diabetes and IGT, 
metformin was associated with greater reduction in BDI score compared to treatment-as-
usual (Krysiak et al., 2017). FBG, insulin resistance and inflammation were not reported 
(Table 1, Table 2). 
 
3.1.3. Incretin-based therapies 
3.1.3.1. Randomised controlled trials  
In a 6-month study of insulin-dependent type 2 diabetes patients, the GLP-1 receptor agonist 
liraglutide was associated with non-significant improvement in BDI score – a secondary 
outcome – compared to usual care (de Wit et al., 2014). FBG improved compared to controls, 
but insulin resistance and inflammation were not measured (Table 1, Table 2).  
 
3.1.3.2. Non-randomised trials 
In a 4-week open label study of patients with comorbid depression and below-average 
cognitive performance, liraglutide was associated with significant reduction in depressive 
symptoms (Mansur et al., 2017), as a secondary outcome. However, this did not correlate 
with reduction in FBG or insulin resistance, and inflammation was not measured (Table 1, 
Table 2). 
 
3.1.4. Insulin 
In a 3-arm randomised trial of 57 patients with poorly controlled type 2 diabetes, insulin was 
not associated with any change in depressive symptoms (Hendra and Taylor, 2004). There 
was no difference in change in glycaemic control between treatment arms, whilst insulin 
resistance and inflammation were not reported (Table 1, Table 2). 
 
3.2. Tolerability 
Gastro-intestinal side-effects were commonly seen in studies of metformin and incretin-based 
therapies. Increased appetite and/or weight gain were reported at significant frequency for 
insulin and for the open-label studies of thiazolidenediones, whereas 6 out of 8 RCT’s of 
thiazolidenediones reported no significant adverse effects (Table 1).  
 
3.3. Statistical analysis  
AC
CE
PT
ED
 M
AN
US
CR
IPT
11 
 
3.3.1. Meta-analysis of pioglitazone 
Meta-analysis was performed for the 8 RCT’s (n=611 patients) of pioglitazone. In random-
effects meta-analysis, there was a significant overall treatment effect on depressive symptoms 
(pooled effect size = -0.68, 95% C.I. -1.12 to -0.24, p=0.003, I2=83.2%), which remained for 
placebo-controlled studies alone (pooled effect size = -0.41 (95% C.I. -0.75 to -0.07), 
p=0.018, I2=60.5%, Nstudies=6). The trim and fill test produced no changes to the results, 
whilst Egger’s test likewise showed no evidence of publication bias (t=-1.70, p=0.14). Of 
note, one metformin-controlled study (Kashani et al., 2013) reported a markedly larger effect 
of pioglitazone than the others. Using the metainf command, the significant effect for 
pioglitazone remained even following removal of this study (pooled effect size = -0.42, 95% 
C.I. -0.71 to -0.14). 
 
 
[Figure 2 here] 
 
  
3.3.2. Meta-regression for pioglitazone 
To help explain the high overall heterogeneity of I2=83.2%, a meta-regression was performed 
for all RCT’s studies testing pioglitazone. Of the covariates selected, data on age and sex 
were available for all studies; data on FBG and baseline severity of depressive symptoms 
were available for 7 studies and data on baseline HOMA-IR were available for 6 studies. 
Data on CRP were insufficient for meta-regression. In the Monte Carlo permutation test, 
female sex (p=0.035) was significantly associated with reduction in depressive symptoms 
across studies. In the random-effects estimate of between-study variance, the effect size was 
significant for proportion of women (β=-0.023 (95% C.I. -0.041 to -0.0041), p=0.016) and 
residual I2 heterogeneity was reduced to 72.5%. Conversely, age (p=0.15), baseline severity 
of depressive symptoms (p=0.58), baseline HOMA-IR (p=1.0) and baseline fasting glucose 
(p=0.92) showed no association with change in depressive symptoms in Monte-Carlo 
permutation tests, and further meta-regression analyses were therefore not performed. 
 
 
3.3.3. Meta-analysis of metformin 
Meta-analysis was performed for the 6 RCT’s of metformin, comprising pooled data from 
2638 patients. Overall, metformin was comparable to controls in its effect on depressive 
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symptoms (pooled effect size = +0.32 (95% C.I. -0.23 to 0.88), p=0.25), although 
heterogeneity was high (I2=94.2%). When stratified by type of controls (placebo or active), 
metformin was non-significantly superior to placebo (pooled effect size -0.49 (95% C.I. -1.04 
to 0.074), p=0.089, I2=92.3%) but was inferior to active controls (pooled effect size 1.32 
(95% C.I. 0.31 to 2.34), p<0.001, I2=90.1%). The trim and fill test produced no changes to 
the results, whilst Egger’s test likewise showed no evidence of publication bias (t=0.74, 
p=0.50). Two studies appeared to be outliers: Guo et al. (favouring metformin) and Kashani 
et al. (very strongly favouring controls). Using the metainf command for all studies, removal 
of Guo et al. changed the overall effect in favour of controls (pooled effect size = 0.65, 95% 
C.I. 0.12 to 1.18). Removal of Kashani et al. did not change the overall effect (pooled effect 
size = -0.02, 95% C.I. -0.49 to 0.45). 
 
[Figure 3 here] 
 
3.3.4. Meta-regression for metformin 
To help explain the high overall heterogeneity of I2=94.2%, a meta-regression was performed 
for studies testing metformin. Data on age, sex and baseline depression severity were 
available for all 6 studies, whereas available data on HOMA-IR (2 studies) and FBG (3 
studies) were insufficient for meta-regression. In the Monte Carlo permutation test, older age 
(p=0.082), male sex (p=0.078) and baseline depression severity (p=0.81) were not associated 
with reduction in depressive symptoms across studies. Due to non-significance and therefore 
risk of false-positive findings, further meta-regression was not performed.  
 
4. Discussion 
 
In this systematic review, we firstly tested whether individual classes of diabetes drugs were 
associated with improvement in depressive symptoms and secondly examined for biological 
correlates of treatment response. In meta-analysis, pioglitazone had a positive overall effect 
on depressive symptoms, although significant heterogeneity between studies was observed. 
Conversely, metformin had a neutral overall effect on depressive symptoms and was inferior 
to active controls, mostly pioglitazone. In random-effects meta-regression, female sex was 
associated with treatment response to pioglitazone, whereas insulin resistance and glycaemic 
control were not. There was some evidence that reduction in inflammation may parallel 
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reduction in depressive symptoms, although data were insufficient to test this statistically. 
Incretin-based therapies showed promise in improving depressive symptoms, but data were 
insufficient for meta-analysis. 
 
4.1. Comparison with other studies 
 
4.1.1. Effects of diabetes treatments on depressive symptoms 
One previous meta-analysis has tested the effects on diabetes treatments of depressive 
symptoms (Colle et al., 2017). This analysis focussed on pioglitazone only and included 4 
papers in its meta-analysis. Our calculated I2 heterogeneity was slightly higher than their 
reported value of 71%. Compared to the previous meta-analysis, our study was enhanced by 
including a greater number of studies – including an unpublished study – and broader range 
of covariates, enabling more detailed analysis of candidate mechanisms and better powered 
meta-regression. There has been no previous meta-analysis testing the effects of metformin 
on depressive symptoms.  
 
Despite promising findings from individual studies, clinical trial data for incretin-based 
therapies were not sufficient for meta-analysis in our review. Nevertheless, there is 
observational evidence from previous studies that would support such trials in future. In a 
secondary analysis of the SOUL-D study, patients prescribed incretin-based therapies 
reported improvement in depressive symptoms over 1 year compared to those receiving other 
diabetes treatments (Moulton et al., 2016). Conversely, previous supporting observational 
data for metformin have been fewer and have focussed on small non-diabetes samples (Hahn 
et al., 2006). For insulin, any supporting observational data have been limited to 1-item 
depressed mood measures (Ascher-Svanum et al., 2015), whilst more recent trials of 
intranasal insulin have shown disappointing effects on mood (Cha et al., 2017). 
 
4.1.2. Correlates of treatment response 
In previous interventional studies, treatment of depressive symptoms in isolation has not 
translated consistently into improvements in glycaemic control (Katon et al., 2004; Petrak et 
al., 2015). This has led to a challenge of the behavioural model for the adverse effects of 
depressive symptoms on diabetes outcomes (Moulton et al., 2015). As a possible alternative 
or additional explanation, depressive symptoms and type 2 diabetes may be linked by shared 
biological mechanisms. If this was the case, then this may partly explain why depressive 
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symptoms in type 2 diabetes are less responsive to conventional anti-depressant treatments 
(Moulton et al., 2015; Strawbridge et al., 2015; Uher et al., 2014). In this paper we focussed 
on three candidate mechanisms: insulin resistance, hyperglycaemia and inflammation. 
 
Elevated insulin resistance may increase the risk of incident depressive symptoms (Ford et 
al., 2015). If true, patients with elevated insulin resistance may be expected to experience 
more marked reduction in depressive symptoms following insulin sensitization. However, we 
did not observe these effects for pioglitazone, a potent insulin sensitizer. For glycaemic 
control, studies have more often tested the effects of treating depressive symptoms on 
hyperglycaemia rather than vice versa. In meta-regression, we found that differences in 
elevated blood glucose between studies likewise did not predict improvement in depressive 
symptoms. This is corroborated by observational findings that glycaemia itself does not 
predict worsening in depressive symptoms over time (Fisher et al., 2010a). Collectively, this 
implicates mechanisms other than glycaemia and insulin resistance in the anti-depressant 
effects of pioglitazone.  
 
In our review, we found promising isolated findings to support reduction in inflammation as a 
correlate of improvement in depressive symptoms, although data were insufficient for meta-
regression. In previous research, elevated inflammation has been found in people with 
comorbid depressive symptoms and type 2 diabetes (Hayashino et al., 2014; Laake et al., 
2014) and predicts incident depressive symptoms in the general population (Valkanova et al., 
2013). Moreover, in a secondary analysis of an incident cohort of type 2 diabetes, improved 
depressive symptoms in people receiving incretin-based therapies correlated with reduction in 
CRP but not HbA1c (Moulton et al., 2016). In mechanistic studies, both incretin-based 
therapies have been found to have potent anti-inflammatory effects, as have 
thiazolidenediones (Kapadia et al., 2008; Makdissi et al., 2012).  
 
4.2. Interpretation 
Our findings suggest that repositioning of diabetes treatments could present novel 
opportunities for treating depressive symptoms. Although the best evidence to date supports 
pioglitazone, this is cautioned by high between-study heterogeneity, a lack of large trials and 
the insufficiency of studies for some other drug classes. This highlights the need both for 
larger clinical trials of pioglitazone and trials of other diabetes treatments, such as incretin-
based therapies, targeted at patients with depressive symptoms. Metformin shows little 
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promise in improving depressive symptoms and further trials are not supported by our meta-
analysis. 
 
Mechanistically, neither insulin resistance nor FBG was found to predict treatment response 
to pioglitazone in our analysis. It is noteworthy that female sex predicted treatment response 
to pioglitazone. Although speculative, this finding is consistent with an inflammatory 
hypothesis, as female sex is associated with increased inflammation and added susceptibility 
to the effects of inflammation on depressive symptoms (Derry et al., 2015). An alternative 
explanation is that the anti-depressant properties of pioglitazone occur through direct central 
effects; although only a minority of pioglitazone is thought to cross the blood-brain barrier 
(Heneka et al., 2005), PPARγ receptors are widely expressed in the brain, including in areas 
implicated in depression, such as the hippocampus (Drew et al., 2006). In parallel with 
further mechanistic research, sex-stratified clinical trials are now needed to test whether 
reduction in inflammation is a cause or consequence of improvement in depressive symptoms 
in people with type 2 diabetes.  
 
4.3. Strengths and limitations 
Our review is strengthened by its systematic literature search, combined data collection on 
depression-specific questionnaires and biological correlates, the use of random-effects meta-
analysis to account for heterogeneity, and inclusion of published- and unpublished literature. 
The review was further enhanced by meta-regression analysis, which including a wide range 
of covariates selected a priori and use of Monte Carlo permutation analysis to reduce the risk 
of false-positive associations. We were also able to perform the first meta-analysis of 
metformin for depressive symptoms, which is important because of its widespread use in 
clinical practice. Limitations of our review included the variable quality of included studies, 
several of which tested depressive symptoms as a secondary outcome, but this was necessary 
when hypotheses are being generated by modelling and pilot data. Inclusion of studies that 
did not specifically recruit depressed patients may have led to underestimation of treatment 
effects. Because of the relatively small number of studies, the meta-regression analysis may 
have been underpowered, and others (such as inflammation) were too infrequently reported to 
be tested as a covariate. Finally, the use of averages of patient characteristics instead of 
individual patient data may have further limited power to detect relationships and assumes 
that the relationship with patient averages across trials is the same as the relationship for 
patients within trials (Thompson and Higgins, 2002). 
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4.4. Summary 
Repositioning of diabetes treatments shows promise for treating comorbid depressive 
symptoms. In particular, thiazolidenediones and incretin-based therapies may improve 
depressive symptoms, although there are limited studies on the latter. Conversely, metformin 
shows little benefit. Anti-depressant effects of pioglitazone appear not to be explained by 
improvements in glycaemic control and insulin resistance. Larger, mechanistically informed 
trials are now needed, testing different classes of diabetes treatments, stratified by sex and 
including longitudinal measures of innate inflammation. 
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Figure Legends 
 
Figure 1  
PRISMA flow diagram of literature search 
 
Figure 2 
Random-effects meta-analysis of standardised mean difference in depressive symptoms for 
pioglitazone group compared to controls 
 
Figure 3 
Random-effects meta-analysis of standardised mean difference in depressive symptoms for 
metformin group compared to controls 
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Figure 3 
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SMD (95% CI)
0.53 (0.16, 0.90)
-0.15 (-0.42, 0.13)
1.32 (0.31, 2.34)
-0.03 (-0.11, 0.06)
1.00 (0.46, 1.54)
2.66 (1.80, 3.52)
-0.49 (-1.04, 0.07)
100.00
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17.65
18.28
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19.04
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Table 1: Data extraction for included studies 
 
 
First author, 
year, 
country 
Study type Baseline 
diabetes  status 
No. 
patients 
(male), 
mean 
age±SD  
Neuro-
psychiatric 
comorbidity 
Intervention 
(number of 
patients) 
Control 
therapy 
(number 
of 
patients) 
Study 
duration 
Mean (SD) 
baseline 
depressive 
symptoms; 
primary or 
secondary 
outcome 
Mean (SD) 
change in 
depressive 
symptoms 
(treatment 
group) 
Mean (SD) 
change in 
depressive 
symptoms 
(controls)  
p-value 
treatmen
t vs 
controls 
Adverse 
effectsa  
CCDAN 
Quality 
score /46  
(% of 
max 
score) 
a) Studies recruiting only patients with depression at baseline 
 
Metformin 
 
             
Guo, 2014, 
China 
Double-blind 
RCT 
T2D only 59 (36) 
54± 7.3 
Nil Metformin 1-
2g/day (n=29) 
Placebo 
(n=29) 
24 weeks MADRS 24.0  
(3.7),  
HDRS-17 
20.3  (2.7) 
-8.3  (4.1) -2.0  (3.9) p<0.001 Gastro-
intestinal 
upset 
21 
(45.7%) 
Lustman, 
2018, USA 
Double-blind 
RCT 
Not selected but 
BMI >28.7 
206 (35) 
42.9 
 (N/S)  
Nil Metformin 
2g/day plus 
sertraline 
(n=104) 
Placebo 
plus 
sertraline 
(n=102) 
16 weeks BDI 22.4 
(7.86) 
-18.82 (8.8) -17.5 (7.9) N/R None 24 
(52.2%) 
Thiazolidene
- 
diones 
             
Calabrese, 
2017, USA 
Double-blind 
RCT 
Non-diabetes 37 (13) 
45.1±12.5
  
All bipolar 
disorder, not 
currently 
manic 
Pioglitazone 
15-45mg/day 
(n=17) 
Placebo 
once per 
day  
(n=20) 
8 weeks IDS, baseline 
N/R 
-31.4 (12.4) -24.3 (12.1) No p-
value 
given 
None 21  
(45.6%) 
Kemp, 2012, 
USA 
Open-label 
study 
Abdominal 
obesity or 
metabolic 
syndrome 
23 (3) 
44.6±10.2 
56% history 
of alcohol use 
disorder 
Pioglitazone 
average 
32.7mg /day 
(n=23) 
Nil 12 weeks IDS 40.3 
(8.6), 
QIDS 15.2 
(3.8) 
IDS -21.1 (8.6), 
QIDS -8.1 (3.8), 
both p<0.001 
N/A N/A Appetite 
and 
weight 
gain  
22 
(47.8%) 
Kemp, 2014, 
USA 
Open-label 
study 
Metabolic 
syndrome or 
insulin resistance  
 
34 (15) 
47.8±10.9 
All bipolar 
disorder, not 
currently 
manic. 
Pioglitazone 
average 
27.4mg/day  
(n=34) 
Nil 8 weeks IDS 38.7 
(8.2), 
QIDS 16.1 
(3.4) 
IDS -17.5  
(8.7), 
QIDS -7.2  
(4.3), both 
p<0.001 
N/A N/A Increased 
appetite, 
peripheral 
oedema  
22 
(47.8%) 
Lin, 2015, 
USA 
Double-blind 
RCT  
Non-diabetes 37 (8) 
46.4±13.5 
10.8% bipolar 
disorder 
 
Pioglitazone 
30mg/day 
(n=17)  
Placebo 
(n=16) 
12 weeks HDRS-21  
15.6 (4.9) 
-4.1  (5.5) -2.7  (4.0)  p=0.23 None 27 
(58.9%) 
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Rasgon, 
2010, USA 
Open-label 
study 
Nondiabetic 
insulin resistance 
8 (1) 
51.9±5.6 
Nil Rosiglitazone 
8 mg/day 
(n=8) 
Nil 12 weeks HDRS 
19.9  (5.0) 
-7.8  (N/R),  
p=0.019 
N/A N/A Weight 
gain  
18 
(39.1%) 
Sepanjnia, 
2012, Iran 
Double-blind 
RCT 
Non-diabetes 40 (11) 
32.1±5.4 
Nil Pioglitazone 
30mg/day 
(n=20)  
Placebo  
(n=20)  
6 weeks HDRS-17 
25.4 (3.5) 
-16.7  (3.5)  -13.4  (3.5)  p=0.005 None 35 
(76.1%) 
Zeinoddini, 
2015, Iran 
Double-blind 
RCT 
Non-diabetes 44 (29) 
32.7±4.5 
All bipolar I 
disorder, not 
currently 
manic 
Pioglitazone 
30mg/day 
(n=22) 
Placebo 
(n=22) 
6 weeks HDRS-17 
23.1 (1.8) 
-14.0  (3.2) -11.7  (2.3)  p=0.006 None 31 
(67.4%) 
Metformin 
vs. 
thiazolidene-
diones  
             
Hu, 2015, 
China 
Unblinded  
RCT  
T2D only 
 
 
118 (67) 
64.6±7.2 
All 3 months 
post-stroke 
Pioglitazone 
30 mg/day 
(n=59)  
Metformin 
1g/day 
(n=59)  
13 weeks HDRS-21 
29.1 (5.7) 
-6.5  (3.6)  -3.1  (8.2)  p<0.05 None 28 
(60.9%) 
Kashani, 
2012, Iran 
Double-blind 
RCT 
Drug-dependent 
diabetes 
excluded  
40 (0) 
20.8±4.0 
Nil Pioglitazone 
30mg/day 
(n=20)  
Metformin 
1.5g/day 
(n=20) 
6 weeks HDRS-17  
15.1 (1.7) 
-5.6  (2.1)  -1.3  (0.9) p<0.001 None 33 
(71.7%) 
Incretin-
based 
therapies 
             
Mansur, 
2017, 
Canada,  
Open-label 
study 
Drug-dependent 
diabetes 
excluded 
19 (8) 
38.2±7.8 
All below-
average 
cognitive 
performance 
Liraglutide 
1.8mg/day 
(n=19) 
None 4 weeks HDRS-17 
12.6  (N/R) 
-3.8 (5.5), 
p=0.022 
N/A N/A Severe 
nausea 
18 
(39.1%) 
b) Studies not specifically selecting for depression at baseline 
 
Metformin 
 
             
Ackermann, 
2009, USA 
Double-blind 
RCT 
Impaired glucose 
tolerance 
 
2155  
(698) 
50.6±10.7 
Nil Metformin 
1.7g/day 
(n=1073)  
Placebo 
(n=1082) 
52 weeks BDI  
4.6  (4.6) 
−0.7  (4.0), 
p<0.001  
−0.58  
(4.5), 
p<0.001 
N/R Gastro-
intestinal 
upset 
36 
(78.2%) 
Jamilian, 
2017, Iran 
Double-blind 
RCT 
No selection  60 (0) 
28.1±4.1 
Nil Metformin 
1.5g/day 
(n=30) 
Myo-
inositol 
2g/day 
(n=30) 
12 weeks BDI 
15.51 (4.6) 
0.3 (0.7)  -1.0 (1.7) p=0.03 Not 
reported 
29  
(63.0%) 
Krysiak, 
2017, Poland 
Non-
randomised, 
open-label 
study 
T2D or 
prediabetes, 
HbA1c<9.5% 
87 (0) 
37.8±4.0 
Nil Metformin 
1.7-3g/day  
(n=45) 
Treatmen
t as usual 
(n=42)  
26 weeks BDI-II  
11.6  (3.3) 
-1.2  (3.4) +0.5  (3.35)  p<0.05 None  22 
(47.8%) 
Thiazolidene
-diones 
             
Roohafza, 
2014, Iran 
Double-blind 
RCT 
Non-diabetic 
metabolic 
syndrome 
85 (35) 
51.4±9.4 
 
 
Nil Pioglitazone 
30mg/day 
(n=53)  
Placebo 
(n=51)  
24 weeks HADS-D  
5.8  (3.9) 
-2.2  (3.3) -1.5  (4.0) p=0.011 None 28 
(60.9%) 
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Simuni, 2015, 
USA 
Double-blind 
RCT 
Non-diabetes 
 
 
210  
(148) 
59.7±9.9 
All 
Parkinson’s 
disease 
Pioglitazone 
15mg/day 
(n=72) or 
45mg/day 
(n=67) 
Placebo 
(n=71) 
44 weeks GDS-15  
1.4  (1.6) 
+0·3 (2.0)  +0·2  (2.3) N/R Weight 
gain 
30 
(65.2%) 
Insulin              
Hendra, 
2004, UK 
Randomised 3-
arm open label 
trial 
T2D on oral 
therapy  
57 (28) 
69.9± 6.2 
Nil Insulin 
variable dose 
(n=38)  
Continue 
tablets 
(n=19) 
26 weeks HADS  
5.6 (3.4) 
-0.9  (3.4)  +0.7  (3.5) Non-
significant 
Weight 
gain 
22 
(47.8%) 
Incretin-
based 
therapies 
             
De Wit, 2014, 
Netherlands 
Unblinded RCT  T2D on insulin 
 
50 (31) 
58±9.0 
Nil Liraglutide 
1.8 mg/day  
(n=26)  
Standard 
therapy 
(n=24)  
26 weeks BDI-II  
9.5 (8.0) 
−1 (2)  0 (1) p=0.46 Nausea 
and 
vomiting 
33 
(71.7%) 
 
Significant effects are highlighted in bold (5% α-level used). 
 
Key: BD, bipolar disorder; BDI, Beck Depression Inventory; DSM, Diagnostic and Statistical Manual of Mental Disorders; HADS; hospital anxiety and depression scale; HDRS, Hamilton Depression Rating Scale; IDS, 
Inventory of Depressive Symptomatology; MADRS, Montgomery-Asberg Depression Rating Scale; MDD, major depressive disorder; N/R, not reported; OD once per day; PCOS, polycystic ovarian syndrome; PHQ-9, 
Patient Health Questionnaire-9; QIDS; Quick Inventory of Depressive Symptomatology; RCT, randomised controlled trial; SD, standard deviation; T2D, type 2 diabetes. 
 
aAdverse effects presented where significantly more frequent in treatment group than controls, or for open-label studies where incidence is 10% or more. 
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Table 2: Effects of treatments on glycaemia, insulin resistance and innate inflammation for included studies  
 
First author, year, 
country 
Mean (SD) 
baseline fasting 
glucose (mg/dL) 
and HbA1c (%)  
Mean (SD) change 
in fasting glucose 
(mg/dL) and HbA1c 
(%) for intervention 
vs controls, p-value 
Mean (SD) baseline 
insulin resistance 
Mean (SD) change 
in insulin resistance 
for intervention vs 
controls, p-value 
Mean (SD) 
baseline hs-CRP 
(mg/L) 
Mean (SD) change in 
hs-CRP (mg/L) for 
intervention vs 
controls, p-value 
Correlation with depression 
a) Studies recruiting only patients with depression at baseline 
 
 
Biguanides 
 
 
     
Guo, 2014, China HbA1c 7.92 (0.7) 
 
HbA1c -1.52 (0.59) 
vs +0.19 (0.60), 
p<0.001 
N/R 
 
 
N/R N/R N/R N/R 
Lustman, 2018, USA 
 
N/R N/R N/R N/R N/R N/R N/R 
 
 
Thiazolidenediones 
       
 
Calabrese, 2017, 
USA 
N/R N/R N/R N/R N/R N/R N/R 
Kemp, 2012, USA FBG 98.85 (11.1) FBG −8.2 (13.3), 
p=0.01 
(uncontrolled) 
Log-HOMA-IR 1.23 
(0.62) 
 
Log-HOMA-IR -0.81 
(0.75), p<0.001 
Log-hs-CRP 1.99 
(0.78) 
−0.87 (0.72), p<0.001 Reduction in HOMA-IR correlated with 
improvement in depression severity (r=0.46, 
p=0.048) 
Kemp, 2014, USA FBG 105.2 (24.5) FBG -7.7 (3.8), 
p=0.01 
(uncontrolled) 
HOMA-IR 6.28 (3.67); 
ISI 1.90 (0.75) 
HOMA-IR -0.89 
(4.83), p=0.27; 
ISI +0.98 (1.41), 
p<0.001 
6.03 (6.68) -3.03 (2.14), p=0.01 
and trend decrease in 
IL-6 (-0.42 (0.46), 
p=0.06) 
Significant correlation between change in 
IDS and change in IL-6 (r=0.44, p=0.01). 
Lin, 2015, USA FBG 97.61 (11.53)  N/R HOMA-IR 3.09 (1.78)  
 
N/R N/R N/R N/R 
Rasgon, 2010, USA FBG 101.2 (14.2) N/R Matsuda Index 2.37 
(0.72) 
 
+0.87 (0.96), p=0.053    
Sepanjnia, 
2012, Iran 
FBG 89.05 (12.03); 
HbA1c 5.65 (0.6)  
N/R HOMA-IR 1.43 (0.21)  N/R N/R N/R N/R 
Zeinoddini, 2015, 
Iran 
FBG 88.0 (11.92)  FBG -1.7 (12.35) vs 
+0.4 (10.91), p=0.79; 
HbA1c +0.1 (0.6) vs 
+0.1 (0.652), p=0.58 
N/R  N/R N/R N/R N/R 
 
Metformin vs. 
Thiazolidenediones 
       
Hu, 2015, China FBG 166.86 
(30.78); 
HbA1c 8.75 (1.60) 
 
N/R HOMA-IR 4.76 (no SD)  N/R N/R N/R N/R 
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Kashani, 2012, Iran FBG 100.57 (22.81)  FBG -4.3 (19.50) vs -
4.5 (20.11), p=0.83 
HOMA-IR 3.66 (0.95)  -0.16 (0.85) vs -0.14 
(0.94), p=0.41 
N/R N/R No correlation between HDRS change and 
HOMA-IR at end of the study (r=0.20, 
p=0.21) 
Incretin-based 
therapies 
       
Mansur, 2017, 
Canada,  
FBG 89.1 (9.0) 
HbA1c 5.28 (0.25) 
FBG -8.28 (8.1), 
p<0.001 
HOMA2-IR 1.01 (0.53) +0.11 (0.55), p=0.20 N/R N/R Non-significant correlations between change 
in HDRS and changes in glucose (r=0.096, 
p=0.72) and HOMA2-IR (r=0.11, p=0.69) 
b) Studies not specifically selecting for depression at baseline 
 
Biguanides 
 
       
Ackermann, 2008, 
USA 
FBG 106.5 (8.5); 
HbA1c 5.91 (0.5)  
FBG -0.23 (0.65) vs 
+0.03 (0.65) 
ISI 0.19 (0.13)  
HOMA-IR 7.0 (no SD)  
Log ISI +0.11 ± 0.02 
vs +0.041±0.02, 
p=0.51; 
HOMA-IR -1.2 vs 
+0.2 (no p-value)  
3.34 (3.68) -0.35 (3.00) vs -0.12 
(2.44), p<0.05  
N/R 
Krysiak, 2017, 
Poland 
FBG 135.04 (12.58) FBG -21.89 (no SD)  HOMA-IR 4.29 (1.24) -2.23 (no SD)  N/R N/R N/R 
 
Jamilian, 2017, Iran N/R N/R N/R N/R N/R N/R N/R 
 
Thiazolidenediones 
 
       
Roohafza, 2014, Iran FBG 97.97 ± 12.92 FBG -0.19 (16.23) vs 
+1.02 (11.19), 
p=0.56 
HOMA-IR 3.33 (1.39) -1.02 (1.22) vs -0.24 
(1.87) p=0.077 
3.14 (2.03)  -1.05 (1.61) vs +0.11 
(1.34), p=0.04 
Change in HOMA-IR in pioglitazone group 
not correlated with change in HADS 
(??=0.14; p=0.15). 
Simuni, 2015, USA N/R  
 
N/R N/R N/R N/R N/R N/R 
Insulin 
 
       
Hendra, 2004, UK HbA1c 9.7 (1.7) HbA1c -0.7 (1.5) vs -
1.1 (1.6) , no p-value 
N/R N/R N/R N/R N/R 
Incretin-based 
therapies 
       
De Wit, 2014, 
Netherlands 
HbA1c 7.34 (0.7)  HbA1c −0.77 (0.11) 
vs +0.01 (0.12), 
p<0.001 
N/R N/R N/R N/R N/R 
 
Significant effects are highlighted in bold (5% α-level used). 
 
FBG values are converted to mg/dL where reported in other units.  
 
Key, N/R, not reported; FBG, fasting blood glucose; hs-CRP, high-sensitivity C-reactive protein; HDRS, Hamilton Depression Rating Scale; HOMA-IR, Homeostasis Model of Insulin Resistance; IL-6, interleukin-6; ISI, 
Insulin Secretory Index; N/R, not reported. 
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